Transactive response DNA-binding protein 43 (TDP-43) proteinopathy: the complex biological and clinical findings in limbic-predominant age-related TDP-43 encephalopathy (LATE) neuropathological changes, limbic-predominant amnestic neurodegenerative syndrome, and other mixed age-related major neurocognitive disorders

• Published in: Current opinion in psychiatry Vol. 38; no. 5; p. 341
• Main Authors: Radanovic, Marcia, Passos Neto, Carlos Eduardo Borges, Monteiro, Luiz Henrique, Forlenza, Orestes Vicente
• Format: Journal Article
• Language: English
• Published: United States 01.09.2025
• Subjects: Aging; Dementia; DNA-Binding Proteins - metabolism; Humans; Limbic System - pathology; Neurodegenerative Diseases - pathology; TDP-43 Proteinopathies - diagnosis; TDP-43 Proteinopathies - genetics; TDP-43 Proteinopathies - pathology; mixed neuopathologies; dementia; limbic-predominant amnestic neurodegenerative syndrome; transactive response DNA-binding protein of 43 kDa; limbic-predominant age-related TDP-43 encephalopathy neuropathological changes
• ISSN: 1473-6578
• DOI: 10.1097/YCO.0000000000001025

As the term limbic-predominant age-related transactive response DNA-binding protein 43 (TDP-43) encephalopathy (LATE) was coined in 2019, more than 200 articles addressing the subject were published. This review aims to provide an updated synthesis of knowledge regarding LATE-NC as a cause of age-related neurodegeneration and cognitive decline while addressing the challenges posed by overlapping neuropathologies in aging populations. LATE-NC is marked by TDP-43 deposition in limbic structures, such as the amygdala and hippocampus, and is often associated with cognitive decline resembling Alzheimer's disease, though with a slower progression in isolated cases. The frequent coexistence of LATE-NC with other neuropathologies, particularly Alzheimer's disease neuropathologic changes (ADNC) and Lewy body dementia (LBD), exacerbates dementia severity and complicates diagnosis and treatment. Recent efforts have established clinical criteria for in-vivo diagnosis, including neuroimaging markers like hippocampal atrophy and limbic hypometabolism. Genetic studies have identified key risk genes, including GRN, TMEM106B, SORL1, and APOE, while biomarker development in cerebrospinal fluid (CSF) and blood remains in its early stages. The review highlights the importance of multidisciplinary research and clinical approaches in addressing the complexities of neurodegenerative diseases involving TDP-43 proteinopathy, enhancing diagnostic accuracy, and developing effective treatments tailored to individual patient profiles.